Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15767395 | 0.81 | CACNA1H (0.49) | — | |
| SCHEMBL10397230 | 0.78 | PDE10A (0.57) | CHEK1PDE10AKDM4EDDAH1POLB | |
| SCHEMBL15767180 | 0.77 | CHEK1 (0.41) | CHEK1PDE10APARP1KDM4EDDAH1 | |
| SCHEMBL1917210 | 0.76 | MGAM (0.47) | — | |
| SCHEMBL7964155 | 0.75 | CHEK1 (0.58) | CHEK1PDE10APARP1KDM4EDDAH1 | |
| SCHEMBL1917492 | 0.75 | PSMB8 (0.49) | CHEK1KDM4EDDAH1POLB | |
| SCHEMBL9754832 | 0.75 | ALDH1A1 (0.46) | CHEK1PDE10AKDM4EDDAH1POLB | |
| SCHEMBL13672554 | 0.74 | CHEK1 (0.41) | CHEK1CYP1A2CYP2C9PDE10APARP1 | |
| SCHEMBL9224298 | 0.73 | KDM4E (0.54) | CHEK1PARP1KDM4E | |
| SCHEMBL9434820 | 0.73 | CHEK1 (0.39) | CHEK1CYP1A2CYP2C9PDE10AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081213-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-20110201640-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2327690-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010016549-A1 | TRICYCLIC COMPOUND | 協和発酵キリン株式会社 (JP) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201640-A1 | TRICYCLIC COMPOUND | PPARG, PPARA, PPARD | CHEK1 4214/4885CYP1A2 1020/4885CYP2C9 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.